We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The European Commission continues to scrutinize the pharmaceutical sector and patent settlement agreements between innovator and generic pharmaceutical companies
